Board of Directors
Drew Senyei, M.D. Enterprise Partners
Andrew E. Senyei, M.D., has served on our board of directors as chairman of the board since April 2000. Dr. Senyei has been a managing director and a general partner of Enterprise Partners, a venture capital firm, since 1987. Dr. Senyei was a founder of Molecular Biosystems and, prior to joining Enterprise Partners, was a practicing clinician and adjunct associate professor of obstetrics, gynecology, and pediatrics at the University of California, Irvine. He serves on the boards of directors of numerous private health care companies. Dr. Senyei obtained his M.D. from Northwestern University and completed his residency training at the University of California, Irvine, Medical Center.
Tim Buono Aura Equity Partners, LLC
Timothy M. Buono has served on our board of directors since March 2000. Mr. Buono is a founder and member of Aura Equity Partners, LLC, a private equity firm focused on growth-oriented investments in companies within the consumer-driven health and personal care markets. From 1997 to 2008, Mr. Buono served as vice president of Tullis-Dickerson & Co., Inc., a venture capital firm with a focus on health care. During this time, he was also a partner in the general partner entities of its sponsored venture capital funds. From 1994 to 1997, he served as senior vice president, business development, for Health Partners, Inc., a health care services company. From 1993 to 1994, Mr. Buono served as director, business development, for Occupational Health Resources, Inc., a health care services company. From 1990 to 1993, Mr. Buono served as an associate of Tullis-Dickerson & Co., Inc. From 1988 to 1990, Mr. Buono was a financial and operations analyst for Shaffer-Clarke. Mr. Buono is a director of a number of privately held companies. He received his B.A. in Economics from Connecticut College in 1988, and completed an Executive Program at Columbia University’s Graduate School of Business in 2003.
Michael Henos Alliance Technology Ventures
Michael A. Henos has served on our board of directors since 2001. From 1993 to the present, Mr. Henos has served as managing general partner of Alliance Technology Ventures, L.P., based in Atlanta, Georgia. Mr. Henos served as a general partner of Aspen Ventures, an early-stage venture capital partnership, from 1991 to 2001. Mr. Henos previously served as a vice president of 3i Ventures Corporation, the predecessor of Aspen Ventures, from 1986 to 1991. From 1984 to 1986, Mr. Henos served as a health care consultant with Ernst & Young, specializing in venture financing of startup medical technology companies. Before joining Ernst & Young, Mr. Henos served in a variety of operating management positions and co-founded and served as chief executive officer of ProMed Technologies, Inc. Mr. Henos is the chairman of the board of directors of both Inhibitex, Inc., a publicly held clinical-stage biopharmaceutical company, and AtheroGenics, Inc., a publicly held biopharmaceutical company. Mr. Henos received his B.S. and MBA from the University of California, Los Angeles.
Robert E. Curry, Ph.D. Alliance Technology Ventures
Robert E. Curry, Ph.D., has served on our board of directors since February 2002. Since July 2002, Dr. Curry has served as a venture partner at Alliance Technology Ventures, L.P., based in Atlanta, Georgia. From July 2001 to July 2002, Dr. Curry was engaged as a consultant to DLJ Capital Corporation, a wholly owned subsidiary of Credit Suisse First Boston (USA), Inc., or CSFB. He joined the Sprout Group, or Sprout, a submanager of various venture capital funds within the CSFB organization, as a general partner in May 1991. Prior to joining Sprout, Dr. Curry served in various capacities with Merrill Lynch R&D Management and Merrill Lynch Venture Capital from 1984, including as president of both organizations from January 1990 to May 1991. Previously, Dr. Curry was a vice president of Becton, Dickinson and Company, a pharmaceutical company, from May 1980 to July 1984, and general manager of the Diagnostics Systems Division of Bio-Rad Laboratories Inc., a clinical diagnostic and life sciences research company, from August 1976 to May 1980. Currently, he is a director of numerous privately held companies as well as the chairman of the board and a trustee of Keck Graduate Institute, a not-for-profit organization. He is also currently the acting chief executive Officer of SensysMedical, Inc. Dr. Curry received a B.S. from the University of Illinois, and M.S. and Ph.D. in chemistry from Purdue University.
Laurence R. McCarthy, Ph.D. Ampersand Ventures
Laurence R. McCarthy, Ph.D., joined our board in 2008. He is a venture partner with Ampersand Ventures and president of Scientific Technologies and Solutions, LLC. Dr. McCarthy was President, CEO, chairman, and CTO of Focus Diagnostics and later served as its CTO following the company’s acquisition by Quest Diagnostics. Prior to this, he was president for the U.S. Diagnostics Division of Boehringer Mannheim; and vice president and general manager and vice president R&D for Becton Dickinson & Co. Dr. McCarthy’s academic experience includes faculty positions at Johns Hopkins School of Medicine, University of North Carolina School of Medicine, and Cornell University School of Medicine, as well as serving as a Laboratory Director at the Memorial Sloan-Kettering Cancer Center and at the North Carolina Memorial Hospital. Dr. McCarthy received his Ph.D. in Microbiology from the University of New Hampshire and his B.S. in Biology from St. Anselm College.
Karin Eastham, M.B.A.
Karin Eastham joined our board in 2008. Most recently, Ms. Eastham was the executive vice president, chief operating officer, and trustee for the Burnham Institute for Medical Research since 2004. Prior to this, she was the senior vice president of finance and the chief financial officer for Diversa Corporation. She has also served in similar senior level management roles at Combichem, Inc., Cytel Corporation and Boehringer Mannheim Diagnostics. Ms. Eastham currently serves on the boards of directors for multiple life science companies including Illumina, Inc., and Amylin Pharmaceuticals, Inc. She also serves on the boards of Tercica, Inc. and SGX Pharmaceuticals, Inc., which have entered into definitive merger agreements pursuant to which such companies will be acquired by Ipsen, S.A. and Eli Lilly and Company, respectively, subject to various conditions including stockholder approval. Ms. Eastham earned her M.B.A. in Finance and B.S. in Accounting from Indiana University, and is a member of the American Institute of Certified Public Accountants and the California Society of Certified Public Accountants. Ms. Eastham is also a Certified Director.
Tina S. Nova, Ph.D. President, Chief Executive Officer, and Co-founder
Tina S. Nova, Ph.D., has served as our president and chief executive officer, and a member of our board of directors, since March 2000. From 1994 to January 2000, Dr. Nova served as chief operating officer and president of Nanogen, Inc., a provider of molecular diagnostic tests, where she was a co-founder. From 1992 to 1994, Dr. Nova served as chief operating officer of Selective Genetics, a targeted therapy biotechnology company. She currently serves as a member of the board of directors of Arena Pharmaceuticals, Inc. and Cypress Bioscience, Inc., both publicly held clinical-stage biopharmaceutical companies. She also serves on the board of trustees of the University of San Diego and was a former life science sector representative to the Independent Citizen’s Oversight Committee overseeing the California Stem Cell Initiative (Proposition 71). Dr. Nova holds a B.S. degree in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside.
Christine A. White, M.D.
Christine A. White, M.D., became a member of the Board of Directors in January 2009. Dr. White was with Biogen Idec, Inc., a biopharmaceutical company, from 1996 to 2005, where she held several senior positions, most recently as senior vice president, Global Medical Affairs. From 1994 to 1996, Dr. White served as the director of clinical oncology research at the Sidney Kimmel Cancer Center in San Diego and from 1984 to 1994, Dr. White was on the clinical staff and held various positions in the Department of Medicine at Scripps Memorial Hospitals in La Jolla and Encinitas, California, most recently as chairman of the Department of Medicine. Dr. White serves as a member of the board of directors at Arena Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in drugs for cardiovascular, central nervous system, inflammatory, and metabolic diseases. She also serves as a member of the board of directors at Pharmacyclics, Inc, a pharmaceutical company developing products to treat cancer and other diseases. Dr. White holds a B.A. in Biology and an M.D. from the University of Chicago, and is board certified in both Internal Medicine and Medical Oncology.